Premium
Homegrown private equity firms CX Partners and Samara Capital are scouting for investment opportunities in companies that make bulk drugs and may involve two of their Limited Partners in any potential deal, two people familiar with the matter told VCCircle. Bulk drugs, known as active pharmaceutical ingredients (APIs) in industry parlance, ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
